Atrium Therapeutics, Inc.

NASDAQ:RNA

Biotechnology

Healthcare
$6.64 +1.28%

+$0.16 today

Market cap
$143.23M
Beta
0.42
P/E (TTM)
-3.3
EPS (TTM)
-$3.78
52W Low $11.40High $16.77

Volume 0.22M

Average 0.35M

RNA Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Atrium Therapeutics, Inc.NASDAQ: RNA

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue of $151K in Q1 FY2026

Q1 FY2026 cost of revenue was $151K.

Context

  • Cost of revenue amounted to 0.0% of revenue in FY2025.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$151K— QoQ
Last fiscal yearDec 2025
$0— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Cost of Revenue vs competitors

How RNA compares with its peers on the latest reported figures

No competitor Cost of Revenue figures are available to compare.

Atrium Therapeutics, Inc.

NASDAQ:RNA

Intrinsic Alpha fair value

Locked

Current Price

$6.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.